Ceva to purchase selected Merial assets from Boehringer Ingelheim

Ceva has agreed a deal with Boehringer Ingelheim to purchase certain assets of Merial, the animal health business that Boehringer Ingelheim is acquiring from Sanofi.

The binding put option agreement has been arranged as part of Boehringer Ingelheim's business swap deal with Sanofi, which will see Sanofi swap its Merial division for Boehringer Ingelheim's consumer healthcare unit.

Ceva will acquire certain animal health vaccines and pharmaceuticals from the Merial portfolio for swine, bovine and companion animals, as well as related intellectual property, manufacturing processes and research and development activities.

The package contains the Circovac, Progressis, Mucosiffa, Parvovax, Parvoruvax, Equioxx, Genixine and Ketofen brands, though the Circovac and Equioxx deals exclude the US and the Ketofen transfer does not apply in Canada.

It is hoped that this agreement will facilitate the approval process for Boehringer Ingelheim's acquisition of Merial from Sanofi.

Dr Marc Prikazsky, chairman and chief executive officer of Ceva Sante Animale, said: "We are highly committed to further develop these successful brands and to continue providing customers with innovative veterinary products to meet their current and future needs."

With over 20 years of experience within the animal health market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current animal health roles we have available, you can search for the latest job roles, register your details, or contact the team today.